Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

The Best Marijuana Stocks in 2016

By Keith Speights - Updated May 24, 2017 at 3:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Marijuana stocks Axim Biotechnologies, Corbus Pharmaceuticals, Aurora Cannabis, and GW Pharmaceuticals soar in 2016.

History might someday note 2016 as the year of marijuana. After the November elections, 28 states now allow use of medical marijuana. Support for legalization of the drug is at an all-time high in the U.S. As you might expect, marijuana stocks have been hot in 2016. Here's why Axim Biotechnologies ( AXIM 0.72% ), Corbus Pharmaceuticals ( CRBP -6.96% ), Aurora Cannabis ( ACB -5.37% ), and GW Pharmaceuticals ( GWPH ) stood out as the best this year among marijuana stocks with market caps of at least $200 million.

A pill bottle containing marijuana on a prescription pad

Image source: Getty Images.

Hemp-based chewing gum

Not only is Axim Biotechnologies one of the best marijuana stocks of the year, it's also the best-performing biotech stock of 2016 so far. Axim's shares have skyrocketed more than 2000% year to date.

The company made less than $35 million in revenue during the first three quarters of 2016 and lost over $4.6 million during the period. So why did the stock shoot up so much? Investors were excited about the potential for Axim's hemp-based chewing gum.

Axim plans to launch its CanChew chewing gum as a food supplement in 2017. The company also intends to initiate multiple clinical studies for the chewing gum, including a trial evaluating use of the product in treating chronic pain and spasticity in patients with multiple sclerosis.

Mid-stage success

Corbus Pharmaceuticals is another marijuana stock that also ranked among the top biotech stocks of the year. Corbus' shares have soared more than 380% year to date.

The driver behind the company's success in 2016 came from its sole pipeline candidate, Resunab. In November, Corbus announced positive results from a mid-stage study of the experimental drug in treating system sclerosis. Those results from the Resunab study were better than what the company expected.

Resunab is also the focus of two other mid-stage clinical studies. Results from a clinical trial evaluating the drug in treating cystic fibrosis are expected in the first quarter of 2017. Corbus anticipates wrapping up enrollment in another mid-stage study of resunab as a potential treatment for dermatomyositis in the second quarter of next year.

Canadian cannabis

Aurora Cannabis is one of the top medical marijuana companies in Canada. It's also one of the fastest-growing marijuana stocks of 2016, with shares up over 380%.

The company began selling medical marijuana in Jan. 2016. In just 10 months, Aurora registered 9,000 active patients. The company is now generating revenue of more than $1 million per month.

More growth could be on the way. Aurora acquired CanvaxRx, the largest medical cannabis counseling network in Canada with more than 10,000 registered patients. The company is expanding its facilities to provide the capability to produce over 70,000 kg annually of medical marijuana. Aurora also gained approval from Health Canada earlier this year to produce derivative cannabis products.

Quality counts

GW Pharmaceuticals' shares performed well in 2016, but the stock's year-to-date increase of over 65% pales in comparison with the gains achieved by Axim, Corbus, and Aurora. There are other marijuana stocks not mentioned in this list that also outperformed GW Pharmaceuticals. So why is the stock included among the best of the year? Because of its quality.

While Axim turned in a sizzling stock performance, the company has a grand total of six full-time employees. GW Pharmaceuticals had 369 employees in 2015. Corbus Pharmaceuticals' great mid-stage results came from a study with 33 patients. GW Pharmaceuticals reported impressive results for Epidiolex from three late-stage clinical studies, the most recent of which included 255 patients. Aurora has been in business a little over a year. GW was founded in 1998.

The bottom line is that GW Pharmaceuticals is a solid company with a track record of research and development and a promising late-stage candidate. Epidiolex could reach peak annual sales of $3 billion if approved.

Axim, Corbus, and Aurora could be big winners again in 2017. However, my view is that GW Pharmaceuticals remains the best overall marijuana stock over the long run.

Marijuana stocks have been hotter than a firecracker lit at both ends. Are they the right investment for you?

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

GW Pharmaceuticals plc Stock Quote
GW Pharmaceuticals plc
Corbus Pharmaceuticals Holdings, Inc. Stock Quote
Corbus Pharmaceuticals Holdings, Inc.
$0.77 (-6.96%) $0.06
AXIM Biotechnologies, Inc. Stock Quote
AXIM Biotechnologies, Inc.
$0.36 (0.72%) $0.00
Aurora Cannabis Stock Quote
Aurora Cannabis
$5.81 (-5.37%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/03/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.